Abivax shares jump 40% after Phase 3 data show no excess cancer risk for ulcerative colitis drug

Abivax reported new safety data from its Phase 3 trial of obefazimod in ulcerative colitis. The data indicated malignancy rates among trial participants were comparable to background rates observed in ulcerative colitis patients, alleviating earlier concerns about a potential cancer signal.

Following the release, the company's stock rose nearly 40% on the day. Abivax also completed an $800 million sale of its U.S.-listed shares, further boosting liquidity.

Analysts had previously praised the drug’s efficacy, and the safety clarification removes a key uncertainty for investors.